CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
CDK4/6 inhibitors have become game-changers in the treatment of estrogen receptor-positive (ER+) breast cancer, and in combination with endocrine therapy are the standard of care first-line treatment for ER+/HER2-negative advanced breast cancer. Although CDK4/6 inhibitors prolong survival for these patients, resistance is inevitable and there is currently no clear standard next-line treatment. There is an urgent unmet need to dissect the mechanisms which drive intrinsic and acquired resistance to CDK4/6 inhibitors and endocrine therapy to guide the subsequent therapeutic decisions. We will review the insights gained from preclinical studies and clinical cohorts into the diverse mechanisms of CDK4/6 inhibitor action and resistance, and highlight potential therapeutic strategies in the context of CDK4/6 inhibitor resistance.
|ISBN||2296-634X (Print) 2296-634X (Electronic) 2296-634X (Linking)|
|Authors||Zhou, F. H.; Downton, T.; Freelander, A.; Hurwitz, J.; Caldon, C. E.; Lim, E.|
|Publisher Name||Front Cell Dev Biol|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/37035239|